Unknown

Dataset Information

0

Widespread brain distribution and activity following i.c.v. infusion of anti-β-secretase (BACE1) in nonhuman primates.


ABSTRACT:

Background and purpose

The potential for therapeutic antibody treatment of neurological diseases is limited by poor penetration across the blood-brain barrier. I.c.v. delivery is a promising route to the brain; however, it is unclear how efficiently antibodies delivered i.c.v. penetrate the cerebrospinal spinal fluid (CSF)-brain barrier and distribute throughout the brain parenchyma.

Experimental approach

We evaluated the pharmacokinetics and pharmacodynamics of an inhibitory monoclonal antibody against β-secretase 1 (anti-BACE1) following continuous infusion into the left lateral ventricle of healthy adult cynomolgus monkeys.

Key results

Animals infused with anti-BACE1 i.c.v. showed a robust and sustained reduction (~70%) of CSF amyloid-β (Aβ) peptides. Antibody distribution was near uniform across the brain parenchyma, ranging from 20 to 40 nM, resulting in a ~50% reduction of Aβ in the cortical parenchyma. In contrast, animals administered anti-BACE1 i.v. showed no significant change in CSF or cortical Aβ levels and had a low (~0.6 nM) antibody concentration in the brain.

Conclusion and implications

I.c.v. administration of anti-BACE1 resulted in enhanced BACE1 target engagement and inhibition, with a corresponding dramatic reduction in CNS Aβ concentrations, due to enhanced brain exposure to antibody.

SUBMITTER: Yadav DB 

PROVIDER: S-EPMC5659992 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC7533042 | biostudies-literature
| S-EPMC6004850 | biostudies-literature
| S-EPMC4086426 | biostudies-literature
| S-EPMC2793532 | biostudies-literature
| S-EPMC4159447 | biostudies-literature
| S-EPMC4070451 | biostudies-literature
| S-EPMC4773915 | biostudies-literature
| S-EPMC343820 | biostudies-literature
| S-EPMC7553790 | biostudies-literature
| S-EPMC9594110 | biostudies-literature